Skip to main content
. 2013 May 29;19(17-18):1960–1971. doi: 10.1089/ten.tea.2012.0455

FIG. 2.

FIG. 2.

In vitro 3D pellet and scaffold-based culture systems. (A, B) In vitro pellet culture. (A) Quantification of the glycosaminoglycan (GAG)/DNA ratio for pellets generated by nasal chondrocytes (NC) cultured with chondrogenic medium supplemented or not with 3.75 μg/mL of bevacizumab. (B) Analysis at mRNA level of Sox9, collagen (types I and II), and VEGF genes. (C, D) In vitro scaffold-based culture. (C) Quantification of the GAG/DNA ratio of cartilaginous constructs generated by NC loaded on FIB control scaffold, HA-FIB either alone, or functionalized by the supplementation of 3.75 (HA-FIB-B3.75) or 5 (HA-FIB-B5) μg/mL of bevacizumab. (D) Analysis at mRNA level was also performed for Sox9, collagen (types I, II, and X), VEGF, and chondromodulin genes. *p<0.01.